Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 832049, 7 pages
http://dx.doi.org/10.1155/2015/832049
Review Article

Deep Response in Multiple Myeloma: A Critical Review

1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
2Department of hematology, Hospital 12 de Octubre, Unidad CRIS, CNIO, University of Madrid, Spain

Received 21 September 2015; Accepted 23 November 2015

Academic Editor: Francesco Di Raimondo

Copyright © 2015 Mariateresa Fulciniti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Chapman, M. S. Lawrence, J. J. Keats et al., “Initial genome sequencing and analysis of multiple myeloma,” Nature, vol. 471, no. 7339, pp. 467–472, 2011. View at Publisher · View at Google Scholar
  2. G. J. Morgan, B. A. Walker, and F. E. Davies, “The genetic architecture of multiple myeloma,” Nature Reviews Cancer, vol. 12, no. 5, pp. 335–348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Kyle, E. D. Remstein, T. M. Therneau et al., “Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma,” The New England Journal of Medicine, vol. 356, no. 25, pp. 2582–2590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Barlogie, J. Shaughnessy, G. Tricot et al., “Treatment of multiple myeloma,” Blood, vol. 103, no. 1, pp. 20–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Rosiñol, A. Oriol, A. I. Teruel et al., “Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study,” Blood, vol. 120, no. 8, pp. 1589–1596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. F. S. Miguel, R. Schlag, N. K. Khuageva et al., “Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 448–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Barlogie, A. Mitchell, F. Van Rhee, J. Epstein, G. J. Morgan, and J. Crowley, “Curing myeloma at last: defining criteria and providing the evidence,” Blood, vol. 124, no. 20, pp. 3043–3051, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Martinez-Lopez, J. Blade, M.-V. Mateos et al., “Long-term prognostic significance of response in multiple myeloma after stem cell transplantation,” Blood, vol. 118, no. 3, pp. 529–534, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Gay, A. Larocca, P. Wijermans et al., “Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients,” Blood, vol. 117, no. 11, pp. 3025–3031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. B. G. M. Durie, J.-L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Cavo, S. V. Rajkumar, A. Palumbo et al., “International myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation,” Blood, vol. 117, no. 23, pp. 6063–6073, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Blade, D. Samson, D. Reece et al., “Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant,” British Journal of Haematology, vol. 102, no. 5, pp. 1115–1123, 1998. View at Publisher · View at Google Scholar
  13. S. V. Rajkumar, J.-L. Harousseau, B. Durie et al., “Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1,” Blood, vol. 117, no. 18, pp. 4691–4695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Brioli, G. J. Morgan, B. Durie, and E. Zamagni, “The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma,” Expert Review of Hematology, vol. 7, no. 1, pp. 13–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Cavo, C. Terragna, G. Martinelli et al., “Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma,” Blood, vol. 96, no. 1, pp. 355–357, 2000. View at Google Scholar · View at Scopus
  16. F. E. Davies, P. D. Forsyth, A. C. Rawstron et al., “The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma,” British Journal of Haematology, vol. 112, no. 3, pp. 814–819, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Ferrero, M. Ladetto, D. Drandi et al., “Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival,” Leukemia, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Galimberti, E. Benedetti, F. Morabito et al., “Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation,” Leukemia Research, vol. 29, no. 8, pp. 961–966, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Martinez-Lopez, E. Fernández-Redondo, R. García-Sánz et al., “Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: results from a GEM/PETHEMA study,” British Journal of Haematology, vol. 163, no. 5, pp. 581–589, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Paiva, J. Almeida, M. Pérez-Andrés et al., “Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders,” Cytometry Part B: Clinical Cytometry, vol. 78, no. 4, pp. 239–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Paiva, M. Chandia, N. Puig et al., “The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma,” Haematologica, vol. 100, no. 2, pp. e53–e55, 2015. View at Publisher · View at Google Scholar
  22. B. Paiva, J. Martinez-Lopez, M.-B. Vidriales et al., “Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma,” Journal of Clinical Oncology, vol. 29, no. 12, pp. 1627–1633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Paiva, J. J. van Dongen, and A. Orfao, “New criteria for response assessment: role of minimal residual disease in multiple myeloma,” Blood, vol. 125, no. 20, pp. 3059–3068, 2015. View at Publisher · View at Google Scholar
  24. E. Zamagni, F. Patriarca, C. Nanni et al., “Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation,” Blood, vol. 118, no. 23, pp. 5989–5995, 2011. View at Publisher · View at Google Scholar
  25. A. C. Rawstron, J. A. Child, R. M. de Tute et al., “Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study,” Journal of Clinical Oncology, vol. 31, no. 20, pp. 2540–2547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Martinez-Lopez, J. J. Lahuerta, F. Pepin et al., “Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma,” Blood, vol. 123, no. 20, pp. 3073–3079, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Rawstron, W. M. Gregory, R. M. de Tute et al., “Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction,” Blood, vol. 125, no. 12, pp. 1932–1935, 2015. View at Publisher · View at Google Scholar
  28. S. G. O'Brien, F. Guilhot, R. A. Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. H. E. White, J. Hedges, I. Bendit et al., “Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale,” Clinical Chemistry, vol. 59, no. 6, pp. 938–948, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. B. Jones, “On a new substance occurring in the urine of a patient with mollities ossium,” Philosophical Transactions of the Royal Society of London, vol. 138, pp. 55–62, 1848. View at Publisher · View at Google Scholar
  31. S. Singhal, E. Vickrey, J. Krishnamurthy, V. Singh, S. Allen, and J. Mehta, “The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios,” Blood, vol. 114, no. 1, pp. 38–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M.-C. Kyrtsonis, T. P. Vassilakopoulos, N. Kafasi et al., “Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma,” British Journal of Haematology, vol. 137, no. 3, pp. 240–243, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. F. van Rhee, V. Bolejack, K. Hollmig et al., “High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis,” Blood, vol. 110, no. 3, pp. 827–832, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. G. P. Mead and M. T. Drayson, “Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients,” Blood, vol. 114, no. 8, p. 1717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. M. Giarin, L. Giaccone, R. Sorasio et al., “Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma,” Clinical Chemistry, vol. 55, no. 8, pp. 1510–1516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Kapoor, S. K. Kumar, A. Dispenzieri et al., “Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma,” Journal of Clinical Oncology, vol. 31, no. 36, pp. 4529–4535, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Martínez-López, B. Paiva, L. López-Anglada et al., “Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality,” Blood, vol. 126, no. 7, pp. 858–862, 2015. View at Publisher · View at Google Scholar
  38. H. Ludwig, G. Slavka, W. Hubl et al., “Usage of HLC-ratio, FLC-ratio, Ife, PBMC infiltration and isotype suppression at best response reveals isotype suppression as most powerful parameter for identification of multiple myeloma patients with long survival,” ASH Annual Meeting Abstracts, vol. 120, no. 21, p. 1817, 1817. View at Google Scholar
  39. H. Ludwig, D. Milosavljevic, N. Zojer et al., “Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients,” Leukemia, vol. 27, no. 1, pp. 213–219, 2013. View at Publisher · View at Google Scholar
  40. C. E. Chee, S. Kumar, D. R. Larson et al., “The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma,” Blood, vol. 114, no. 13, pp. 2617–2618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Fernández de Larrea, N. Tovar, M. Rozman et al., “Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression,” Biology of Blood and Marrow Transplantation, vol. 17, no. 7, pp. 1084–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Grimwade, P. Vyas, and S. Freeman, “Assessment of minimal residual disease in acute myeloid leukemia,” Current Opinion in Oncology, vol. 22, no. 6, pp. 656–663, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Brüggemann, T. Raff, and M. Kneba, “Has MRD monitoring superseded other prognostic factors in adult ALL?” Blood, vol. 120, no. 23, pp. 4470–4481, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes, “Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods,” Blood, vol. 111, no. 4, pp. 1774–1780, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Paiva, N. C. Gutiérrez, L. Rosiñol et al., “High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma,” Blood, vol. 119, no. 3, pp. 687–691, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Puig, M. E. Sarasquete, A. Balanzategui et al., “Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry,” Leukemia, vol. 28, no. 2, pp. 391–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kalina, J. Flores-Montero, Q. Lecrevisse et al., “Quality assessment program for EuroFlow protocols: summary results of four-year (2010–2013) quality assurance rounds,” Cytometry A, vol. 87, no. 2, pp. 145–156, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Ladetto, M. Brüggemann, L. Monitillo et al., “Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders,” Leukemia, vol. 28, no. 6, pp. 1299–1307, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Reghunathan, C. Bi, S. C. Liu et al., “Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival,” Oncotarget, vol. 4, no. 8, pp. 1230–1240, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. C. S. Zent, C. S. Wilson, G. Tricot et al., “Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation,” Blood, vol. 91, no. 9, pp. 3518–3523, 1998. View at Google Scholar · View at Scopus
  51. B. Paiva, T. Paino, J.-M. Sayagues et al., “Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.,” Blood, vol. 122, no. 22, pp. 3591–3598, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Z. Usmani, A. Mitchell, S. Waheed et al., “Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3,” Blood, vol. 121, no. 10, pp. 1819–1823, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. W. G. Miller, G. L. Myers, M. L. Gantzer et al., “Roadmap for harmonization of clinical laboratory measurement procedures,” Clinical Chemistry, vol. 57, no. 8, pp. 1108–1117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. R. Tate, R. Johnson, and K. Sikaris, “Harmonisation of laboratory testing,” Clinical Biochemist Reviews, vol. 33, no. 4, pp. 121–122, 2012. View at Google Scholar · View at Scopus
  55. M. Ladetto, G. Pagliano, S. Ferrero et al., “Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 2077–2084, 2010. View at Publisher · View at Google Scholar · View at Scopus